市場調査レポート

非アルコール性脂肪性肝炎 (NASH):有病率・開発中の薬剤・法規制ガイドライン・市場機会の分析:地域別

Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies

発行 MP Advisors 商品コード 346132
出版日 ページ情報 英文 65 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
非アルコール性脂肪性肝炎 (NASH):有病率・開発中の薬剤・法規制ガイドライン・市場機会の分析:地域別 Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies
出版日: 2015年12月01日 ページ情報: 英文 65 Pages
概要

C型肝炎の治療薬の売上は2014年に100億ドルを超え、肝臓病の治療薬はメガブロックバスターとなりうることを示しました。非アルコール性脂肪性肝炎 (NASH) も同様に高い収益性が期待できるでしょう。

当レポートでは、非アルコール性脂肪性肝炎 (NASH) の治療薬の市場について調査し、NASHの概要、可能性のあるNASH治療薬、開発中の薬剤の状況と開発企業、既存薬のNASHへのリポジショニングの取り組みなどをまとめています。

第1章 エグゼクティブサマリー

第2章 非アルコール性脂肪性肝炎 (NASH) の概要

  • NASH治療において可能性のある標的
  • パイプライン薬
  • 主なマイルストーン
  • M&A/ライセンシング取引の推進因子
  • 市場機会の見通し

第3章 開発中の製品・競合環境

  • 主なNASH治療薬・開発企業
    • Obeticholic Acid:Intercept Pharmaceuticals/大日本住友製薬
    • Elafibranor:Genfit
    • Multiple programs:Gilead
    • Emricasan:Conatus Pharmaceuticals
    • Aramchol:Galmed Pharmaceuticals
    • Cenicriviroc:Tobira Therapeutics
    • IMM-124E:Immuron
    • GR-MD-02:Galectin Therapeutics
    • TD139:Galecto Biotech
    • SHP626:Shire
    • PXS4728A:Boehringer Ingelheim
  • NASHへの既存薬の適応
    • Remogliflozin etabonate:Islet Sciences/BHV pharma
    • Lipaglyn (saroglitazar):Cadila Healthcare
    • Victoza (liraglutide):Novo Nordisk

第4章 NASH:病因・病原・診断・現在の治療法

  • 原因・症状・病態形成・診断
  • 現在の治療法:漢方薬を含む

第5章 薬事上の経路

  • 臨床試験における課題
  • 可能性のある臨床試験設計とエンドポイント

第6章 付録

目次
Product Code: 4485

Sales of Hepatitis C drugs crossed ~$10bn in 2014 proving that treatments for liver disease could become mega-blockbusters and Non-Alcoholic SteatoHepatitis (NASH) is expected to be equally lucrative. Improved diagnosis rate and change in treatment guidelines along with defined clinical trials endpoint are the concerns for the emerging therapy. US FDA is expected to release guidelines for the clinical trial in CY16 and this should accelerate the development of the drugs targeting NASH.

NASH is the progressive form of Non-Alcoholic Fatty Liver Disease - NAFLD. While NASH can reverse itself, in many cases, the resulting liver scarring causes a patient's liver to harden and failure to work properly. It is estimated that NASH affects 2 to 5% of the US population. Other developed countries such as Europe and Japan also have similar or higher incidence of NASH disease. Due to the varying physical and metabolism traits across various geographies, development of drugs for NASH is facing difficulty. In Japan, the prevalence of NASH is rising although the population is not typically overweight. Countries like India and China with bigger population and changes in lifestyles face a greater risk of NASH along with other lifestyle diseases like Diabetes and Cardiovascular related complexities.

As per the US Association of Liver Disease, of those who develop NASH, ~15-25% will progress to end stage liver disease (ESLD) and hepatocellular carcinoma (HCC) over 10-20 years. Today, 1/3rd of Liver transplants and HCC are caused by NASH and the total cost burden of this on US is over ~$5 billion per year. Only new treatments in NASH could lead to a cut in this major cost burden along with improving quality of life.

Since a new innovation in NASH has been enlightened, the interest in companies developing drugs for NASH has also gone up. In Jan. 2015, Gilead Sciences (GILD) acquired Phenex Pharma's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH) and other Liver Diseases. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also entered into an exclusive agreement for the pipeline products which are being developed for NASH with a potential deal value of ~$450-600mn.

This report will provide detailed analysis on NASH disease and Drugs in development in broader pharma market. This report list all the drugs in clinical trial and their design and the population recruited, also tells about the pathways representing possible targets for the treatment of NASH.

Table of Contents

1. Executive Summary

2. Overview of NASH

  • 2.1. Possible targets for the treatment of NASH
  • 2.2. Drugs in the pipeline
  • 2.3. Key Milestones
  • 2.4. Drivers of M&A/ Licensing deals in NASH
  • 2.5. NASH disease market opportunity to 2025

3. Products in Development and Competitive Landscape

  • 3.1. Key Drugs/Companies Developing Drugs Against NASH
    • 3.1.1. Obeticholic Acid - Intercept Pharmaceuticals/ Dainippon Sumitomo
    • 3.1.2. Elafibranor - Genfit
    • 3.1.3. Multiple programs - Gilead
    • 3.1.4. Emricasan - Conatus Pharmaceuticals
    • 3.1.5. Aramchol - Galmed Pharmaceuticals
    • 3.1.6. Cenicriviroc - Tobira Therapeutics
    • 3.1.7. IMM-124E - Immuron
    • 3.1.8. GR-MD-02 - Galectin Therapeutics
    • 3.1.9. TD139 - Galecto Biotech
    • 3.1.10. SHP626 - Shire
    • 3.1.11. PXS4728A - Boehringer Ingelheim
  • 3.2. Repurposed Drugs for NASH
    • 3.2.1. Remogliflozin etabonate - Islet Sciences/BHV pharma
    • 3.2.2. Lipaglyn (saroglitazar) - Cadila Healthcare
    • 3.2.3. Victoza (liraglutide) - Novo Nordisk

4. NASH - Etiology, Pathogenesis, Diagnosis and Current Treatment

  • 4.1. Cause, Symptoms, Pathogenesis, Diagnosis
  • 4.2. Current treatment including Herbal Medicine

5. Regulatory Pathway

  • 5.1. Challenges in trials using endpoints to define clinically meaningful benefits
  • 5.2. Potential Clinical Trial Design for NASH and Endpoints

6. Annexure

Back to Top